Date & Time
Monday, April 29, 2024, 8:00 AM - 9:00 AM
Plenary Session: Prostate Cancer Update for Corrections

Prostate cancer is the most common malignancy encountered in corrections. While screening guidelines are well standardized, therapy options have become increasingly more complicated. Active surveillance remains a reasonable therapy option while robotic surgery can be considered the default therapy of choice in terms of cost and long-term complications. Advances in radiation therapy have expanded treatment options and can reduce the number of off-site transports. The role of new therapeutics, including hormonal options and novel radiopharmaceuticals, will be discussed, along with their effect on physicians' treatment decisions and patient outcomes.

Educational Objectives

  • Identify patients appropriate for PSA screening
  • Review treatment options for patients with low, intermediate, and high-risk prostate cancer
  • Discuss hypofractionated radiation therapy


Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC